ClinicalTrials.gg
TerminatedNCT05900141OLEUpdated Nov 10, 2026

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

A Phase 3 interventional study of Pelacarsen in Hyperlipoproteinemia (a), sponsored by Novartis Pharmaceuticals. Terminated at 9 sites in Germany. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
Updated Nov 10, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This non-randomized, open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants in Germany with hyperlipoproteinemia(a) and established cardiovascular disease who have successfully completed the double-blind parent study (CTQJ230A12302). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint.

Read the detailed description

This study will allow to evaluate a long-term safety and tolerability of pelacarsen (TQJ230) 80 mg QM in patients. All consenting participants from the parent study who meet the eligibility criteria will be participating in this open label extension study. The maximum duration of this study is approximately 5 years.

02

Conditions studied

  • Hyperlipoproteinemia (a)

Keywords

  • Lipoprotein(a)
  • Cardiovascular disease
  • Apheresis
  • Post trial access
  • pelacarsen (TQJ230)
03

In context

Hyperlipoproteinemias

35 studies on the registry are indexed under Hyperlipoproteinemias; 6 are open to participants now.

This study's enrollment of 41 is below the median of 84 across 29 interventional studies indexed under Hyperlipoproteinemias.

Browse Hyperlipoproteinemias studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Participant has successfully completed the parent study and is considered safe to participate by Investigator's clinical judgement.

Exclusion criteria

Exclusion Criteria:

  • Any medical condition(s) that may put the participant at risk in the investigator's opinion
  • Pregnant or nursing (lactating) women
  • Women of , unless they are using effective methods of during dosing and for 16 weeks (= 5 times the terminal half-life) after stopping of study medication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Pelacarsen (TQJ230)

    open-label pelacarsen 80 mg

    Drug: Pelacarsen

Interventions

  • Pelacarsen 80mg s.c. monthly

    Also known as: TQJ230

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse events (AEs) or serious adverse events (SAEs), including changes in laboratory evaluations, vital signs qualifying and reported as AEs.

    Evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants with elevated Lp(a) and established cardiovascular disease who have competed the parent study

    Time frame: 60 months

  2. Duration of drug exposure

    Duration of drug exposure will be collected

    Time frame: 60 months

Secondary outcomes

  1. Number of lipoprotein apheresis sessions performed yearly for year 1, 2, 3, 4 and 5

    Evaluate the long-term effect of pelacarsen on the need for lipoprotein apheresis.

    Time frame: 60 months

  2. Absolute change in Lp(a) compared to baseline of the parent study.

    Evaluate the long-term effect of pelacarsen on Lp(a) change.

    Time frame: month 1, month 3, month 6, month 9, month 12, then every 6 months during OLE (up to 60 months)

  3. Percentage change in Lp(a) compared to baseline of the parent study.

    Evaluate the long-term effect of pelacarsen on Lp(a) change.

    Time frame: month 1, month 3, month 6, month 9, month 12, then every 6 months during OLE (up to 60 months)

07

Study locations

9 sites
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60431, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Cloppenburg, 49661, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2023 to primary completion in Oct 2026, 36 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Aug 2028 → Oct 2026 and completion Aug 2028 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jun 12, 2023
StartActual
Sep 29, 2023
Primary completionActual
Oct 15, 2026was Aug 2028
CompletionActual
Oct 15, 2026was Aug 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
changed Nov 10, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 Germany)
  • Novartis Investigative Site · Munich, Germany
  • Novartis Investigative Site · Würzburg, Germany
  • Novartis Investigative Site · Dresden, Germany
Show 3 removed
  • Novartis Investigative Site · Dresden, Germany
  • Novartis Investigative Site · München, Germany
  • Novartis Investigative Site · Würzburg, Germany
Nov 10, 2026
Primary completion
Aug 24, 2028→Oct 15, 2026 (actual)
Nov 10, 2026
Study completion
Aug 24, 2028→Oct 15, 2026 (actual)
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Active, not recruiting→Terminated
    Why stopped Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
    3 sites added, 3 sites removed
    Show 3 added (3 Germany)
    • Novartis Investigative Site · Munich, Germany
    • Novartis Investigative Site · Würzburg, Germany
    • Novartis Investigative Site · Dresden, Germany
    Show 3 removed
    • Novartis Investigative Site · Dresden, Germany
    • Novartis Investigative Site · München, Germany
    • Novartis Investigative Site · Würzburg, Germany
    Primary completion Aug 24, 2028→Oct 15, 2026 (now actual)
    Study completion Aug 24, 2028→Oct 15, 2026 (now actual)
    + 2 other changes: verification date and description
  2. Oct 14, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05900141
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Sep 29, 2023
Primary completion
Oct 15, 2026
Completion
Oct 15, 2026
Last update
Nov 10, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelacarsen

Start the discussion